Core Viewpoint - Huanggang Yong'an Pharmaceutical Co., Ltd., a significant shareholder of Qianjiang Yong'an Pharmaceutical Co., Ltd., plans to reduce its shareholding without affecting the company's control [1][2]. Group 1: Shareholding Reduction Announcement - On July 25, 2025, the company disclosed a pre-announcement regarding the planned share reduction by its controlling shareholder, Huanggang Yong'an, who holds 10,529,232 shares (3.5731% of total shares) [1]. - Huanggang Yong'an intends to reduce its holdings by up to 2,632,300 shares (0.8933% of total shares) within three months following the pre-announcement [1]. Group 2: Implementation of Share Reduction - On September 9, 2025, the company reported that Huanggang Yong'an had completed its share reduction plan, having sold 410,000 shares (0.1391% of total shares) on September 4, 2025 [2][3]. - The reduction was executed at a price range of 17.02 to 19.02 yuan per share [2]. Group 3: Compliance and Impact - The share reduction was conducted in compliance with relevant laws and regulations, ensuring no breach of prior commitments [3]. - The reduction will not lead to a change in the company's control or affect its governance structure and ongoing operations [3].
潜江永安药业股份有限公司 关于公司控股股东、实际控制人之一致行动人减持计划实施完成的公告